Pep2Tango Therapeutics is a biotech company developing superior unimolecular multi-receptor agonists for obesity and related disorders. Their lead program in obesity is a first-in-class tetra-receptor peptide agonist peptide that shows superiority to Tirzepatide for weight loss in obesity animal models. Other key product differentiation attributes include selective weight loss from fat mass with preservation of lean mass / muscle. With their cutting-edge peptide platform and promising pipeline, Pep2Tango aims to revolutionize obesity and metabolic disease treatment with better, safer, and more effective therapies.
Company Details
- Employees
- 3
- Founded
- -
- Address
- Potomac, Md 20854, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.pep2tango.com
- Keywords
- using AI.
- HQ
- Potomac, MD
Pep2tango Therapeutics Questions
Pep2Tango Therapeutics's website is http://www.pep2tango.com
Pep2Tango Therapeutics's LinkedIn profile is https://www.linkedin.com/company/pep2tango.com
Pep2Tango Therapeutics has
3 employees.
View email and phone details for 3
employees at Pep2Tango Therapeutics.
Pep2Tango Therapeutics's industry is
Biotechnology Research
Pep2Tango Therapeutics's top competitors are
Enveda,
Sixpeaks Bio,
Seaport Therapeutics,
Metsera,
Antag Therapeutics,
Valora Therapeutics, Inc.,
Abvance Therapeutics,
Versant Ventures,
Trace Neuroscience,
Recode Therapeutics.
Pep2Tango Therapeutics's categories are Biotechnology Research
Pep2Tango Therapeutics's founding year is 2021
